Lancet

Lancet Oncology 2000, 1:94–100.PubMedCrossRef 2. Stiller CA, Pritchard J, Steliarova-Foucher E: Liver cancer in European children: incidence and survival, 1978–1997. Report from the Automated Childhood Cancer Information System project. European Journal of Cancer

2006,42(13):2115–23.PubMedCrossRef 3. Weksberg R, Shuman C, Beckwith JB: Beckwith-Wiedemann syndrome. Eur J Hum Genet 2009,18(1):8–14.CrossRef 4. Hirschman BA, Pollock BH, Tomlinson GE: The spectrum of APC mutations in children with hepatoblastoma from familial adenomatous polyposis kindreds. Journal of buy Ulixertinib Pediatrics 2005,147(2):263–6.PubMedCrossRef 5. Zimmermann A: The emerging family of hepatoblastoma tumours: from ontogenesis to oncogenesis. European Journal of Cancer 2005,41(11):1503–14.PubMedCrossRef 6. Zimmermann A: Pediatric liver tumors and hepatic ontogenesis: common and distinctive pathways. Med Pediatr Oncol 2002,39(5):492–503.PubMedCrossRef 7. Honda

S, et al.: Loss of imprinting of IGF2 correlates with CH5183284 clinical trial hypermethylation of the H19 differentially methylated region in hepatoblastoma. British Journal of Cancer 2008,99(11):1891–9.PubMedCrossRef 8. Rainier S, Dobry CJ, Feinberg AP: Loss of imprinting in hepatoblastoma. Cancer Research 1995,55(9):1836–8.PubMed Ro 61-8048 research buy 9. Lopez-Terrada D, et al.: Histologic subtypes of hepatoblastoma are characterized by differential canonical Wnt and Notch pathway activation in DLK+ precursors. Hum Pathol 2009,40(6):783–94.PubMedCrossRef 10. Adesina AM, et al.: Gene expression profiling reveals signatures characterizing histologic subtypes of hepatoblastoma and global deregulation in cell growth and survival pathways. Hum Pathol 2009,40(6):843–53.PubMedCrossRef

11. Jeng YM, et al.: Somatic mutations of beta-catenin play a crucial role in the tumorigenesis of sporadic hepatoblastoma. Cancer Lett 2000,152(1):45–51.PubMedCrossRef Phosphoribosylglycinamide formyltransferase 12. Koch A, et al.: Childhood hepatoblastomas frequently carry a mutated degradation targeting box of the beta-catenin gene. Cancer Res 1999,59(2):269–73.PubMed 13. Wei Y, et al.: Activation of beta-catenin in epithelial and mesenchymal hepatoblastomas. Oncogene 2000,19(4):498–504.PubMedCrossRef 14. Yamaoka H, et al.: Diagnostic and prognostic impact of beta-catenin alterations in pediatric liver tumors. Oncology Reports 2006,15(3):551–6.PubMed 15. Taniguchi K, et al.: Mutational spectrum of beta-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas. Oncogene 2002,21(31):4863–71.PubMedCrossRef 16. Yamaoka H, et al.: Diagnostic and prognostic impact of beta-catenin alterations in pediatric liver tumors. Oncol Rep 2006,15(3):551–6.PubMed 17. Blaker H, et al.: Beta-catenin accumulation and mutation of the CTNNB1 gene in hepatoblastoma. Genes Chromosomes Cancer 1999,25(4):399–402.PubMedCrossRef 18. Takayasu H, et al.: Frequent deletions and mutations of the beta-catenin gene are associated with overexpression of cyclin D1 and fibronectin and poorly differentiated histology in childhood hepatoblastoma.

Pietenpol, Nashville, TN Bruce A J Ponder, Cambridge, England E

Pietenpol, Nashville, TN Bruce A. J. Ponder, Cambridge, England Eddie Reed, Mobile, AL Margaret A. Shipp, Boston, MA Margaret R. Spitz, Houston, TX Craig B. Thompson, Philadelphia, PA Eileen P. White, Piscataway, NJ The French National Cancer Institute Board of Directors President Dominique Maraninchi, Boulogne-Billancourt, France CEO Pascale Flamant, Boulogne-Billancourt, France Deputy Directors Fabien Calvo, Boulogne-Billancourt, France Directors Christine Bara, Boulogne-Billancourt , France Anne Ramon, Boulogne-Billancourt, France Advisory Board President Jacques Pouyssegur, Nice, France Vice-President James Armitage, Omaha, USA Daniel Louvard, Paris,

France Jean-Pierre Bizzari, Summit, USA Gilles Favre, Toulouse, France Daniel Haller, Philadelphia, USA Jean-Luc Harousseau, Nantes, France Peter Dasatinib ic50 Harper, Londres, United Kingdom Denis Hemon, Villejuif, France Jean-Marie Lehn, Paris, France Michel Marty, Paris,

France Claude Mawas, Marseille, France Jacques Samarut, Lyon, France Bruno Varet, Paris, France Robert Weinberg, Cambridge, USA Program Committee Isaac P. Witz, Tel Aviv, Israel (Chairman) Adriana Albini, Milan, Italy Menashe Bar Eli, Houston, USA Fabien Calvo, Paris, France Yves DeClerck, Los Angeles, USA Wolf H. Fridman, Paris, France Kornelia Polyak, Boston, USA Jacques Pouyssegur, Nice, France Benjamin Sredni, Ramat Gan, Israel Eitan Yefenof, Jerusalem, Israel Smadar Fisher, Conference Coordinator, Tel Aviv, Israel Carbohydrate Conference Secretariat- DIESENHAUS UNITOURS, Tel Aviv, Israel Acknowledgments The Members of the Organizing Committee CHIR-99021 research buy of the 5th International Conference on Tumor Microenvironment: Progression, Therapy & Prevention, express their gratitude and acknowledge the following institutions and companies for their generous support Lead Supporter Millennium Pharmaceuticals, Inc Principal Sponsors The Pikovski Fund, Jerusalem, Israel National Cancer

Institute, NIH Sponsors Supported by an educational donation provided by Amgen Teva Pharmaceutical Industries Ltd European Association for Cancer Selleckchem CYT387 research (EACR) “Cancer Microenvironment” the official journal of the International Cancer Microenvironment Society Roche, France The assistance of Ms. Noa Laks, Ms. Malka Ben Haim and Ms. Linda Brand of Tel Aviv University and Ms. Michal Semo and Ms. Yael Kfir of the TAU Graphic Design Studio, is highly appreciated. Dear Friends and Colleagues, It is with great pleasure that I welcome you to the Fifth International Conference on Tumor Microenvironment: Progression, Therapy & Prevention and to the beautiful city of Versailles. The International Cancer Microenvironment Society (ICMS), the American Association for Cancer Research (AACR) and the National Cancer Institute of France (INCa) have joined forces to organize an outstanding event whose interesting and challenging scientific program covers the most recent developments in basic and translational Tumor Microenvironment research.